Positive Preliminary Findings for Treatment-Resistant Depression

Positive Preliminary Findings for Treatment-Resistant Depression

By: Tomas Ronolski - AllPennyStocks.com News

Thursday, June 2, 2022

Depression is a major illness affecting individuals across the globe. With no known cure, the possibilities of therapies for treatment-resistant depression are an exciting and hopeful prospect.

Medical research company Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), which provides and advances innovative ketamine and psilocybin treatments for depression and related mental health disorders, announced positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression per the company’s press release.

The use of psychedelics for mental health treatment is an innovative solution that is gaining traction and is believed to offer professionals another option to treat patients. 

Canadian shares of Braxia ended Wednesday trade higher in a volatile market.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Will Shares Rise on Milestone Development for AI-Powered Heart Technology?
Shares of this Innovative AI Solutions Firm Rip on Updated Pricing
Slowing Growth Increases Hopes of a Rate Cut Pivot in Canada 
Most Popular
FREE Newsletter


Back to Top